Evelo Biosciences Reviewing Alternatives After Study Didn't Meet Endpoint
By Will Feuer Evelo Biosciences said it is reviewing strategic alternatives after its Phase 2 clinical trial of EDP2939 for the treatment of moderate...
Evelo Biosciences Executive Simba Gill Will Feuer Article Normal Healthcare Life Sciences Specialized Drugs Medications
Source: marketwatch.com